Skip to main content

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has achieved a consensus “Buy” rating from the twenty rating companies that currently cover the company, reports MarketBeat Ratings. Six research analysts rated the stock with a keep recommendation and nine gave the company a buy recommendation. The one-year average price target among brokerage firms that updated their equity coverage in the past year is $ 115.81.

BMRN has been the subject of several analyst reports. SVB Leerink launched coverage on shares of BioMarin Pharmaceutical in a report on Sunday, July 11. They set a “buy” rating and a price target of $ 83.62 for the company. Credit Suisse Group assumed coverage of BioMarin Pharmaceutical shares in a report released on Monday April 26. They set an “outperformance” rating and a price target of $ 102.00 for the company. Morgan Stanley lowered its price target for BioMarin Pharmaceutical shares from $ 85.00 to $ 82.00 and set an “equal weight” rating for the company in a report released on Monday, April 19. Finally, Wedbush reissued a “buy” note and set a price target of $ 141.00 on shares of BioMarin Pharmaceutical in a report released Friday.

Shares of BioMarin Pharmaceutical opened at $ 78.84 on Monday. The company has a fifty-day moving average of $ 80.31. The company has a market cap of $ 14.41 billion, a P / E ratio of 131.40, a PEG ratio of 23.87 and a beta of 0.58. BioMarin Pharmaceutical has a fifty-two week low of $ 71.35 and a fifty-two week high of $ 131.95. The company has a current ratio of 5.32, a quick ratio of 3.66 and a debt ratio of 0.26.

BioMarin Pharmaceutical (NASDAQ: BMRN) last released its quarterly earnings data on Wednesday April 28. The biotech company reported EPS of $ 0.09 for the quarter, beating analyst consensus estimates of $ 0.07 by $ 0.02. The company posted revenue of $ 486.03 million in the quarter, compared to a consensus estimate of $ 445.44 million. BioMarin Pharmaceutical had a net margin of 43.11% and a return on equity of 2.77%. As a group, analysts expect BioMarin Pharmaceutical to post earnings per share of 0.1 for the current year.

In other news, CEO Jean Jacques Bienaime sold 25,000 shares of BioMarin Pharmaceutical in a transaction that took place on Friday, May 7. The shares were sold at an average price of $ 78.12, for a total trade of $ 1,953,000.00. Following the completion of the sale, the CEO now owns 303,839 shares of the company, valued at approximately $ 23,735,902.68. The sale was disclosed in a file with the SEC, accessible through this link. Additionally, CFO Brian Mueller sold 6,709 shares of BioMarin Pharmaceutical in a trade that took place on Friday, May 7. The stock was sold for an average price of $ 79.50, for a total trade of $ 533,365.50. As a result of the sale, the CFO now owns 31,357 shares of the company, valued at approximately $ 2,492,881.50. Disclosure of this sale can be found here. Insiders have sold a total of 59,963 shares of the company valued at $ 4,700,861 in the past 90 days. Company insiders own 1.69% of the company’s shares.

Several large investors have recently changed their holdings in BMRN. Freedman Financial Associates Inc. acquired a new equity interest in BioMarin Pharmaceutical during the 4th quarter for a value of approximately $ 33,000. Steward Partners Investment Advisory LLC increased its stake in BioMarin Pharmaceutical by 189.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 425 shares of the biotech company valued at $ 37,000 after purchasing an additional 278 shares during the period. Sierra Capital LLC acquired a new position in BioMarin Pharmaceutical during the first quarter, valued at approximately $ 38,000. Bessemer Group Inc. increased its stake in BioMarin Pharmaceutical by 1,621.6% during the first quarter. Bessemer Group Inc. now owns 637 shares of the biotech company valued at $ 49,000 after purchasing an additional 600 shares during the period. Finally, Berman Capital Advisors LLC increased its stake in BioMarin Pharmaceutical by 600.0% during the fourth quarter. Berman Capital Advisors LLC now owns 581 shares of the biotech company valued at $ 50,000 after purchasing an additional 498 shares during the period. Institutional investors hold 95.67% of the company’s shares.

Profile of the pharmaceutical company BioMarin

BioMarin Pharmaceutical Inc develops and markets therapies for people with rare diseases and serious and life-threatening medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 which is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Read more: Understanding specialized certificates of deposit

Analyst Recommendations for BioMarin Pharmaceutical (NASDAQ: BMRN)

This instant news alert was powered by storytelling technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured article: What is Elliott Wave Theory?

7 health actions serving innovation in 2021

We all knew that traditional health services were disrupted in 2020. The patient-doctor relationship has gone virtual. During the first months of the pandemic, many people in need of elective surgeries simply did not have this option available to them. And even local pharmacies have taken on a new role in e-commerce as curbside pickup or home delivery of prescription drugs has become the norm.

Unsurprisingly, healthcare stocks took a rough ride last year. Overall, the sector was down 11%, well below the S&P 500 which climbed more than 15%.

However, the market is always looking to the future with a particular eye on innovation. The healthcare sector has many companies that are developing innovative approaches in areas such as gene editing. And other companies are in the advanced testing phase for drugs that can deliver groundbreaking results for conditions that continue to plague our world.

This is the object of this presentation. We have identified 7 healthcare actions that offer innovative ideas that will help achieve better patient outcomes. And in some cases, it will completely revolutionize medicine. These are also the stocks that analysts watch.

Consult the “7 healthcare stocks for innovation in 2021”.

Leave a Reply